Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of the study is to establish clinical evidence for introducing disulfiram and cooper as an active therapy for metastatic breast cancer upon failure of conventional systemic and/or locoregional therapies.

Analyses of the following objectives will be performed in the population of patients with metastatic breast cancer:

Primary efficacy objective:

To evaluate the efficacy of the treatment by assessment of:

• clinical response rate (RR)

• clinical benefit rate (CBR)

Secondary efficacy objectives:

To evaluate the efficacy of the treatment by assessment of:

• time to progression (TTP)

• overall survival (OS)

Pharmacokinetic objectives:

• to determine pharmacokinetic parameters for disulfiram and its active metabolites administered in combination with copper supplements in cancer patient population

Safety objectives:

• to describe safety profile of disulfiram administered in combination with copper supplements

Exploratory objectives:

Parallel analysis to assess (identify) potential candidate surrogate biomarkers of disulfiram efficacy, as well as identification (using proteomic, biochemical and molecular genetic studies) of potential predictive biomarkers of disulfiram sensitivity or resistance will be performed. Surrogate biomarker analysis will focus on in vivo ubiquitin-proteosomal system inhibition, cell cycle and DNA damage.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Marian Hajduch, M.D., Ph.D.; The Institute of Molecular and Translational Medicine, Czech Republic
• Collaborator: University Hospital Olomouc
• Treatments: Copper; Disulfiram

Criteria

Inclusion Criteria:

1. Patients with stage IV breast cancer with metastases demonstrated by appropriate imaging techniques (computer tomography - CT, positron emission tomography - PET or PET/CT, MRI, ultrasound, etc.)

2. Histologically or cytologically confirmed tumor

3. Age of 18 years or more

4. ECOG performance status of 0 - 2

5. Patients have failed, untolerated or refused standard therapeutic modalities

6. Not received systemic anticancer therapy or radiation or had major surgery in last 2 weeks

7. Not currently participating in another study

8. Anticipated survival of at least 2 months

9. Baseline AST and ALT not greater than 2.5 X upper institutional limit

10. Serum copper within normal limits

11. Serum ceruloplasmin > 17 mg/dL

12. Able and willing to sign informed consent and to comply with study procedures

13. Able to ingest oral medications

14. No known allergy to disulfiram or copper

15. Willing to refrain from ingestion of alcoholic beverages while on the study

Exclusion Criteria:

1. Participation in another clinical trial of a therapeutic drug during the past 14 days

2. Addiction to alcohol or drugs

3. Baseline AST or ALT greater than 2.5 X upper institutional limit

4. Unable to ingest oral medications

5. Unable to undergo CT/SPECT scanning because of inability to lie recumbent in the scanner

6. Actively receiving cytotoxic cancer chemotherapy agents

7. Anticipated survival of less than 2 months

8. Women of child-bearing potential who are not using a commonly accepted effective means of contraception; women of child-bearing potential will have negative pregnancy test before enrollment

9. History of active liver disease, including chronic active hepatitis, viral hepatitis (hepatitis B, C and CMV), cholestatic jaundice of any etiology, toxic hepatitis, or cholestatic hepatitis or jaundice with bilirubin greater than 2.0 X upper institutional limit

10. History of Wilson's disease or family member with Wilson's disease

11. History of hemochromatosis or family member with hemochromatosis

12. History of other iron overload syndrome such as hemochromatosis

13. Need for metronidazole, warfarin and/or theophylline medication, the metabolism of which is likely influenced by disulfiram

14. Pregnant women and nursing mothers are not allowed to enroll on this study

15. Patients who are taking medications metabolized by cytochrome P450 2E1, including chlorzoxazone or halothane and its derivatives